From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity-Reference-Cited by-同舟云学术

From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity

Published:2021-04-01 Issue:8 Volume:64 Page:4462-4477
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Abdel-Halim Mohammad¹^ORCID,Sigler Sara²,Racheed Nora A. S.¹,Hefnawy Amr¹,Fathalla Reem K.¹³,Hammam Mennatallah A.¹,Maher Ahmed⁴,Maxuitenko Yulia²,Keeton Adam B.²,Hartmann Rolf W.³^ORCID,Engel Matthias³^ORCID,Piazza Gary A.²,Abadi Ashraf H.¹^ORCID

Affiliation:

1. Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt

2. Departments of Oncologic Sciences and Pharmacology, Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Avenue, Mobile, Alabama 36604, United States

3. Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2.3, D-66123 Saarbrücken, Germany

4. Biochemistry Department, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza 11266, Egypt

Funder

National Cancer Institute

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01120

Reference33 articles.

1. 1,2-Diarylcyclopentenes as Selective Cyclooxygenase-2 Inhibitors and Orally Active Anti-inflammatory Agents